Dawoud B E S, Kent S, Tabbenor O, Markose G, Java K, Kyzas P
Specialty Trainee Oral & Maxillofacial Surgery, Manchester University NHS Foundation Trust, United Kingdom.
Specialty Trainee Oral & Maxillofacial Surgery, University Hospital of Wales, Cardiff, United Kingdom.
Br J Oral Maxillofac Surg. 2022 Dec;60(10):1292-1302. doi: 10.1016/j.bjoms.2022.07.016. Epub 2022 Sep 16.
The commonest cause of microvascular free flap failure is thrombosis at the anastomosis. Pharmacological antithrombotic therapies have been used to mitigate this risk, but they carry the risk of bleeding and haematoma formation. To justify any intervention, it is necessary to evaluate the benefits and balance of risks. This meta-analysis aims to quantify the value of systemic anticoagulation during head and neck free tissue reconstruction. We performed a systematic review on the impact of additional prophylactic antithrombotic therapy on head and neck (H&N) free tissue transfer (on top and above the use of low molecular weight heparin to prevent deep vein thrombosis). We carried a PRISMA-guided literature review, following registration with PROSPERO. All studies analysing the possible impact of prophylactic anticoagulants on free flap surgery in the head and neck were eligible. The primary outcome was perioperative free flap complications (perioperative thrombosis, partial or total free flap failure, thrombo-embolic events, or re-exploration of anastomosis). Secondary outcomes included haematoma formation or bleeding complications requiring further intervention. We identified eight eligible studies out of 454. These included 3531 free flaps for H&N reconstruction. None of the assessed interventions demonstrated a statistically significant improvement in free flap outcomes. Accumulative analysis of all anti-coagulated groups demonstrated an increased relative risk of free flap complications [RR 1.54 (0.73-3.23)] compared to control albeit not statistically significant (p = 0.25). Pooled analysis from the included studies showed that the prophylactic use of therapeutic doses of anticoagulants significantly (p = 0.003) increased the risk of haematoma and bleeding requiring intervention [RR 2.98 (1.47-6.07)], without reducing the risk of free flap failure. Additional anticoagulation does not reduce the incidence of free flap thrombosis and failure. Unfractionated heparin (UFH) consistently increased the risk of free flap complications. The use of additional anticoagulation as 'prophylaxis' in the perioperative setting, increases the risk of haematoma and bleeding.
微血管游离皮瓣失败最常见的原因是吻合口处血栓形成。药物抗血栓治疗已被用于降低这种风险,但它们有出血和形成血肿的风险。为了证明任何干预措施的合理性,有必要评估其益处和风险平衡。这项荟萃分析旨在量化头颈部游离组织重建期间全身抗凝的价值。我们对额外预防性抗血栓治疗对头颈部(H&N)游离组织移植的影响进行了系统评价(在使用低分子量肝素预防深静脉血栓形成之上及之外)。在向PROSPERO注册后,我们进行了一项遵循PRISMA指南的文献综述。所有分析预防性抗凝剂对头颈部游离皮瓣手术可能影响的研究均符合条件。主要结局是围手术期游离皮瓣并发症(围手术期血栓形成、部分或完全游离皮瓣失败、血栓栓塞事件或吻合口再次探查)。次要结局包括需要进一步干预的血肿形成或出血并发症。我们从454项研究中确定了8项符合条件的研究。这些研究包括3531例用于H&N重建的游离皮瓣。所有评估的干预措施均未显示游离皮瓣结局有统计学上的显著改善。与对照组相比,所有抗凝组的累积分析显示游离皮瓣并发症的相对风险增加[风险比(RR)1.54(0.73 - 3.23)],尽管无统计学意义(p = 0.25)。纳入研究的汇总分析表明,预防性使用治疗剂量的抗凝剂显著(p = 0.003)增加了需要干预的血肿和出血风险[RR 2.98(1.47 - 6.07)],而未降低游离皮瓣失败的风险。额外抗凝并不能降低游离皮瓣血栓形成和失败的发生率。普通肝素(UFH)持续增加游离皮瓣并发症的风险。在围手术期将额外抗凝作为“预防措施”使用会增加血肿和出血的风险。